AN2 Therapeutics (ANTX) Receivables (2023 - 2024)
AN2 Therapeutics (ANTX) reported Receivables of $300000.0 for Q4 2024, down 70.0% year-over-year from $1.0 million in Q1 2024, and little changed quarter-over-quarter from $300000.0 in Q2 2024.
AN2 Therapeutics (ANTX) Receivables (2023 - 2024) Analysis & Trends
AN2 Therapeutics (ANTX) has 2 years of Receivables data on file, last reported at $300000.0 in Q4 2024.
- Receivables for Q4 2024 came in at $300000.0, down 70.0% year-over-year; the trailing twelve-month figure through Dec 2024 was $300000.0 (down 70.0% YoY), and the FY2024 annual result was $300000.0, down 70.0% from the prior year.
- Receivables was little changed at $300000.0 in Q4 2024 per ANTX's latest filing, from $300000.0 in the prior quarter.
- Over five years, Receivables peaked at $1.0 million in Q4 2023 and troughed at $300000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 860,679.92 Bn | 860,679.89 Bn | - | - |
| 2 | Belite Bio | 55,284.00 Bn | 55,284.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,206.94 Bn | 16,206.93 Bn | - | - |
| 4 | Legend Biotech | 3,318.00 Bn | 3,317.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Akari Therapeutics | 1,543.84 Bn | 1,543.84 Bn | - | - |
| 6 | Evaxion A | 1,449.11 Bn | 1,449.09 Bn | - | - |
| 7 | Psyence Biomedical | 216.99 Bn | 216.98 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 115.22 Bn | 107.97 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 90.58 Bn | 90.58 Bn | - | - |
| 10 | AN2 Therapeutics | 165.87 Mn | 165.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 300,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Mar 31, 2024 | 500,000.00 |
| Dec 31, 2023 | 1.00 Mn |
| Sep 30, 2023 | 900,000.00 |